Received Apr 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
No additional AE; patient received fi rst doseof GARDASIL 9 on July 19th 2021, second dose on March 18th 2025 and would like to complete the series; This spontaneous report has been received from a healthcare student (Also reported as Nurse, conflicting information) referring to a 27-year-old patient of unspecified gender. The patient's concurrent conditions, medical history, previous drug reactions, drug allergies and concomitant therapies were not provided. On 19-JUL-2021, the patient was vaccinated as prophylaxis with the first dose of HPV rL1 6 11 16 18 31 45 52 58 VLP vaccine (yeast) (GARDASIL 9) (strength, dose, frequency, route of administration, lot #, and expiration date were not provided); and on 18-MAR-2025, the patient was vaccinated with the second dose of HPV rL1 6 11 16 18 31 45 52 58 VLP vaccine (yeast) (GARDASIL 9) (strength, dose, frequency, route of administration, lot #, and expiration date were not provided) (Inappropriate schedule of vaccine administered). No additional adverse event (AE).